Ren R - Search Results

1

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Parikh C, Subrahmanyam R, Ren R. Parikh C, et al. Among authors: ren r. Cancer Res. 2007 Aug 1;67(15):7139-46. doi: 10.1158/0008-5472.CAN-07-0778. Cancer Res. 2007. PMID: 17671181 Free PMC article.

2

Mouse model for NRAS-induced leukemogenesis.

Parikh C, Ren R. Parikh C, et al. Among authors: ren r. Methods Enzymol. 2008;439:15-24. doi: 10.1016/S0076-6879(07)00402-8. Methods Enzymol. 2008. PMID: 18374153

3

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Parikh C, Subrahmanyam R, Ren R. Parikh C, et al. Among authors: ren r. Blood. 2006 Oct 1;108(7):2349-57. doi: 10.1182/blood-2004-08-009498. Epub 2006 Jun 8. Blood. 2006. PMID: 16763213 Free PMC article.

4

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.

Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R. Zhang X, et al. Among authors: ren r. Mol Cell Biol. 2001 Feb;21(3):840-53. doi: 10.1128/MCB.21.3.840-853.2001. Mol Cell Biol. 2001. PMID: 11154271 Free PMC article.

5

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.

Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Shackelford D, et al. Among authors: ren r. Cancer Res. 2006 Dec 1;66(23):11360-9. doi: 10.1158/0008-5472.CAN-06-1774. Cancer Res. 2006. PMID: 17145882

6

Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Cuiffo B, Ren R. Cuiffo B, et al. Among authors: ren r. Blood. 2010 Apr 29;115(17):3598-605. doi: 10.1182/blood-2009-03-213876. Epub 2010 Mar 3. Blood. 2010. PMID: 20200357 Free PMC article.

7

Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.

Jiang J, Gui F, He Z, Li L, Li Y, Li S, Wu X, Deng Z, Sun X, Huang X, Huang W, Han S, Zhang T, Wang Z, Jiao B, Song S, Wang H, Chen L, Zhou D, Liu Q, Ren R, Zhang J, Deng X. Jiang J, et al. Among authors: ren r. Cancer Res. 2017 Jan 1;77(1):175-186. doi: 10.1158/0008-5472.CAN-16-1038. Epub 2016 Oct 10. Cancer Res. 2017. PMID: 27758886

8

Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras.

Liu P, Jiao B, Zhang R, Zhao H, Zhang C, Wu M, Li D, Zhao X, Qiu Q, Li J, Ren R. Liu P, et al. Among authors: ren r. Leukemia. 2016 May;30(5):1225-8. doi: 10.1038/leu.2015.293. Epub 2015 Oct 22. Leukemia. 2016. PMID: 26493479 No abstract available.

9

Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis.

Baum KJ, Ren R. Baum KJ, et al. Among authors: ren r. J Hematol Oncol. 2008 Jun 5;1:5. doi: 10.1186/1756-8722-1-5. J Hematol Oncol. 2008. PMID: 18577264 Free PMC article.

10

A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.

Ning N, Yu Y, Wu M, Zhang R, Zhang T, Zhu C, Huang L, Yun CH, Benes CH, Zhang J, Deng X, Chen Q, Ren R. Ning N, et al. Among authors: ren r. Cancer Res. 2018 Oct 15;78(20):5949-5957. doi: 10.1158/0008-5472.CAN-18-0455. Epub 2018 Aug 22. Cancer Res. 2018. PMID: 30135190

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,593 results

Search Page

Filters